FDA 483 OBSERVATION · #99 OF 1,945 MOST-CITED
Written procedures - product complaint
FDA cited this observation 300 times across 270 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Drug CGMP requires written procedures for the receipt, review, and evaluation of product complaints, including whether a complaint reflects a possible failure of the drug to meet specifications and whether it must be investigated. Device manufacturers face the parallel complaint-handling requirement at 21 CFR 820.198.
Why FDA writes it — FDA cites this when complaint-handling procedures are absent or inadequate, because complaints are an early warning system — without a controlled process to capture, evaluate, and investigate them, a firm misses the field signal that a product or process has failed.
- Establish written procedures defining how complaints are received, logged, reviewed, and evaluated for a possible specification or safety failure.
- Define criteria for when a complaint triggers a formal investigation and link it to your deviation/CAPA system.
- Maintain complaint files with the required findings and follow-up, and trend them to detect recurring issues.
- Complaints handled informally by customer service without a controlled written procedure or quality-unit review.
- No defined threshold for escalating a complaint into an investigation, so real signals are closed out as routine.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.8× the rate of the average FDA-cited firm (30.0% vs 7.8%), across 270 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
You did not establish written procedures for the requirements to review and investigate a product complaint.
You did not establish written procedures for the requirements to review and investigate a product complaint.
You did not establish written procedures for the requirements to review and investigate a product complaint.
You did not establish and follow written procedures for the requirements to review and investigate a product complaint.
You did not establish written procedures for the requirements to review and investigate a product complaint.
You did not establish written procedures for the requirements to review and investigate a product complaint.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →